John P Fruehauf

Summary

Country: USA

Publications

  1. ncbi request reprint Docetaxel and vinorelbine plus GM-CSF in malignant melanoma
    John P Fruehauf
    University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, California 92868, USA
    Oncology (Williston Park) 19:19-22. 2005
  2. ncbi request reprint Assay-assisted treatment selection for women with breast or ovarian cancer
    John P Fruehauf
    Oncotech Inc, 15501 Redhill Avenue Tustin, CA 92780, USA
    Recent Results Cancer Res 161:126-45. 2003
  3. doi request reprint Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma
    John Fruehauf
    University of California, Irvine, Orange, 92868, USA
    Clin Cancer Res 17:7462-9. 2011
  4. pmc Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study
    Leslie M Randall
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 119:417-21. 2010
  5. pmc Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
    Ernest S Han
    University of California Irvine, Orange, CA, USA
    Gynecol Oncol 119:484-90. 2010
  6. pmc Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study
    Shu Yuan Liao
    Department of Epidemiology, University of California at Irvine, School of Medicine, Irvine, CA, USA
    Gynecol Oncol 116:452-8. 2010
  7. ncbi request reprint Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma
    Krishnansu S Tewari
    The Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA
    Gynecol Oncol 98:360-8. 2005
  8. ncbi request reprint In vitro drug response and molecular markers associated with drug resistance in malignant gliomas
    John P Fruehauf
    University of California Irvine Chao Family Clinical Cancer Research Center, Orange, 92868, USA
    Clin Cancer Res 12:4523-32. 2006
  9. pmc Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study
    Leslie M Randall
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 112:583-9. 2009
  10. pmc Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma
    Zeynep Eroglu
    Departments of Medicine, University of California Irvine Medical Center, Orange, CA 92868, USA
    Cancer Chemother Pharmacol 68:1081-7. 2011

Collaborators

Detail Information

Publications34

  1. ncbi request reprint Docetaxel and vinorelbine plus GM-CSF in malignant melanoma
    John P Fruehauf
    University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, California 92868, USA
    Oncology (Williston Park) 19:19-22. 2005
    ..The DVS regimen was active against advanced melanoma in both previously treated and untreated patients. A larger study to confirm the activity of the DVS regimen for stage IV melanoma is currently under way...
  2. ncbi request reprint Assay-assisted treatment selection for women with breast or ovarian cancer
    John P Fruehauf
    Oncotech Inc, 15501 Redhill Avenue Tustin, CA 92780, USA
    Recent Results Cancer Res 161:126-45. 2003
    ..These data suggest that in vitro drug response assays can accurately predict drug resistance and can identify patients who are more or less likely to benefit from a given agent...
  3. doi request reprint Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma
    John Fruehauf
    University of California, Irvine, Orange, 92868, USA
    Clin Cancer Res 17:7462-9. 2011
    ....
  4. pmc Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study
    Leslie M Randall
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 119:417-21. 2010
    ..To investigate the feasibility of performing a fresh-tissue, in vitro radiation resistance assay (IVRRA) in a cooperative group setting and to assess the association of IVRRA results with clinical outcomes...
  5. pmc Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
    Ernest S Han
    University of California Irvine, Orange, CA, USA
    Gynecol Oncol 119:484-90. 2010
    ..Potential predictive/prognostic angiogenic markers were prospectively examined in a phase II trial of bevacizumab in epithelial ovarian cancer (EOC)/primary peritoneal cancer (PPC)...
  6. pmc Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study
    Shu Yuan Liao
    Department of Epidemiology, University of California at Irvine, School of Medicine, Irvine, CA, USA
    Gynecol Oncol 116:452-8. 2010
    ....
  7. ncbi request reprint Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma
    Krishnansu S Tewari
    The Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA
    Gynecol Oncol 98:360-8. 2005
    ..To compare the in vitro drug resistance profiles of advanced stage primary and recurrent epithelial ovarian cancer specimens using the tritiated thymidine uptake assay...
  8. ncbi request reprint In vitro drug response and molecular markers associated with drug resistance in malignant gliomas
    John P Fruehauf
    University of California Irvine Chao Family Clinical Cancer Research Center, Orange, 92868, USA
    Clin Cancer Res 12:4523-32. 2006
    ....
  9. pmc Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study
    Leslie M Randall
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 112:583-9. 2009
    ..To determine whether markers of tumor angiogenesis were associated with progression-free survival (PFS) and overall survival (OS) in women with high-risk, early-stage cervical cancer treated on a phase III trial...
  10. pmc Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma
    Zeynep Eroglu
    Departments of Medicine, University of California Irvine Medical Center, Orange, CA 92868, USA
    Cancer Chemother Pharmacol 68:1081-7. 2011
    ..Granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown activity as an adjuvant melanoma therapy. We carried out a phase II study of these agents in patients with stage IV melanoma...
  11. ncbi request reprint Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer
    Min Ying Su
    Center for Functional Onco Imaging and Chao Family Comprehensive Cancer Center, University of California Irvine, USA
    J Magn Reson Imaging 18:467-77. 2003
    ....
  12. pmc Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture
    Valerie Trapp
    Clinical Pharmacology and Developmental Therapeutics, University of California Irvine Chao Family Comprehensive Cancer Center, 101 The City Drive South, Bld 55, Rm 324, Orange, CA 92868, USA
    Angiogenesis 13:305-15. 2010
    ..This effect was associated with increased melanoma cell expression of tumor suppressor protein 53 and matrix protein TSP1, as well as decreased hypoxia-driven expression of hypoxia inducible factor-1α and inhibition of VEGF production...
  13. doi request reprint Reactive oxygen species: an Achilles' heel of melanoma?
    John P Fruehauf
    University of California Irvine, Chao Family Comprehensive Cancer Center, CA, USA
    Expert Rev Anticancer Ther 8:1751-7. 2008
    ..A recent randomized Phase II trial with elesclomol, an agent that generates ROS, in combination with paclitaxel led to improved patient survival, suggesting that this may be a viable approach to advance the treatment of melanoma...
  14. ncbi request reprint Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study
    Devansu Tewari
    Division of Gynecologic Oncology, University of California Irvine Medical Center, 101 The City Drive South, Orange, CA 92868, USA
    Gynecol Oncol 99:84-91. 2005
    ..To determine the feasibility of integrating an in vitro chemo-radiation response assay (IVRRA) with a gene microarray system to investigate the molecular patterns of expression that contribute to radiation resistance in cervical cancer...
  15. doi request reprint A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder
    Zeynep Eroglu
    Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine, 101 The City Drive South, Orange, CA, USA
    Cancer Chemother Pharmacol 72:263-7. 2013
    ..These findings suggest that GEMOX is an active combination in advanced bladder cancer patients with reduced renal function. ..
  16. ncbi request reprint Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring
    Min Ying Su
    John Tu and Thomas Yuen Center for Functional Onco Imaging, University of California, Irvine Hall 164, Irvine, CA 92697, USA
    Technol Cancer Res Treat 1:479-88. 2002
    ..The vascular properties measured by macromolecular contrast medium may have the potential to serve as early therapeutic efficacy indicators...
  17. doi request reprint The effect of bevacizumab (Avastin) on neuroimaging of brain metastases
    Marlon S Mathews
    Department of Neurological Surgery, University of California Irvine, Orange, CA 92868, USA
    Surg Neurol 70:649-52; discussion 653. 2008
    ..Bevacizumab is a monoclonal antibody that binds to, and inactivates, VEGF and is believed to be antiangiogenic...
  18. ncbi request reprint A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma
    Ricardo J Parker
    Oncotech, Inc, Tustin, CA 92780, USA
    J Neurooncol 66:365-75. 2004
    ..008). At last follow-up, two of three survivors were patients who had tumors IDR/LDR to SN38. These prospective data support the notion that patients should avoid agents to which their tumor demonstrates EDR...
  19. ncbi request reprint In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer
    Noelle Gillette Cloven
    University of California Irvine, Orange, CA 92868, USA
    Gynecol Oncol 92:160-6. 2004
    ..Biomarker profiles (p53, Her-2 neu, and EGFR) were also evaluated to determine if their expression patterns were associated with histology...
  20. ncbi request reprint Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine
    Karen R Sommers
    Division of Hematology Oncology, University of California and Chao Family Comprehensive Cancer Center, Irvine, CA, USA
    Anticancer Drugs 14:659-62. 2003
    ..This report describes a serious potential complication of concurrent gemcitabine and radiotherapy...
  21. ncbi request reprint Mathematical modeling of cancer progression and response to chemotherapy
    Sandeep Sanga
    University of California, Department of Biomedical Engineering, Irvine, 3120, CA 92697 2715, USA
    Expert Rev Anticancer Ther 6:1361-76. 2006
    ....
  22. ncbi request reprint A tale of two growth factors
    John P Fruehauf
    University of California Irvine Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA
    Pharmacotherapy 26:443-4; discussion 444. 2006
  23. ncbi request reprint Reactive oxygen species: a breath of life or death?
    John P Fruehauf
    Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California 92668, USA
    Clin Cancer Res 13:789-94. 2007
    ..This review will cover recent work in ROS-mediated signaling in cancer cells and its potential as a target for developmental therapeutics...
  24. ncbi request reprint Development of an in vitro chemo-radiation response assay for cervical carcinoma
    Bradley J Monk
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, Orange, California 92868, USA
    Gynecol Oncol 87:193-9. 2002
    ..To determine if synergistic effects of radiation (RT) and chemotherapy (chemo) on human cervical carcinoma cell lines and fresh tumor explants could be determined using an in vitro assay...
  25. doi request reprint Redox-related antimelanoma activity of ATN-224
    Valerie Trapp
    Clinical Pharmacology and Developmental Therapeutics, University of California Irvine Chao Family Comprehensive Cancer Center, Orange, California, USA
    Melanoma Res 19:350-60. 2009
    ..These data suggest that strategically tailoring combination regimens that include ATN-224 and target ROS may be a viable approach to advance the treatment of melanoma...
  26. ncbi request reprint Pharmacogenomics of colorectal cancer prevention and treatment
    Hoa Nguyen
    University of California Irvine Chao Family Comprehensive Cancer Center, Orange, California, USA
    Cancer Invest 24:630-9. 2006
    ..This review focuses on current knowledge regarding key mutations and polymorphisms which affect outcomes for colorectal cancer patients, as well as the pharmacogenetics of chemoprevention trials...
  27. ncbi request reprint Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients
    Robert W Holloway
    Walt Disney Memorial Cancer Institute at Florida Hospital, Orlando, FL 32804, USA
    Gynecol Oncol 87:8-16. 2002
    ....
  28. ncbi request reprint Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens
    Robert J Ellis
    Department of Internal Medicine, University of Kansas Medical Center, Kansas City 66160, USA
    Breast Cancer Res Treat 71:95-102. 2002
    ..These results may be helpful for designing possible future trials that evaluate the assay's role in adjuvant chemotherapy selection...
  29. ncbi request reprint In vitro drug resistance versus chemosensitivity: two sides of different coins
    John P Fruehauf
    J Clin Oncol 23:3641-3; author reply 3646-8. 2005
  30. ncbi request reprint Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors
    Marcela G del Carmen
    Department of Gynecology and Obstetrics Department of Oncology, The Johns Hopkins Hospital and Medical Institutions, Baltimore, Maryland, USA
    Cancer 98:1658-63. 2003
    ..Using immunohistochemical methods, we compared the differential expression patterns of various cytokines and growth factors in atypical endometriosis (AE) and EAOC...
  31. ncbi request reprint The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer
    Michael J Goodheart
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa Hospital and Clinics, Iowa City, Iowa, USA
    Clin Cancer Res 11:3733-42. 2005
    ..Multiple angiogenic factors may influence tumor progression and metastasis. Several are modified by the p53 gene. We sought to identify molecular markers for high-risk stage I epithelial ovarian cancers...
  32. ncbi request reprint Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens
    Raymond I Haroun
    Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Neurooncol 58:115-23. 2002
    ....
  33. ncbi request reprint Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression
    Janine G Einspahr
    Department of Medicine, Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Cancer 110:2519-27. 2007
    ..Tumor angiogenesis likely plays a critical role in early development of melanoma, and intermediate biomarkers of angiogenesis could be useful as chemoprevention and prognostic markers...
  34. ncbi request reprint Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator
    Carol J Fabian
    University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Clin Cancer Res 10:5403-17. 2004
    ..We performed a multi-institutional evaluation of arzoxifene in women with newly diagnosed ductal carcinoma in situ or T1/T2 invasive cancer...